Baricitinib (brand name Olumiant®) is a tablet that belongs to a class of medicines called Janus Kinase (JAK) inhibitors.
Tofacitinib (brand name: Xeljanz) belongs to a class of medicines called non-biological disease modifying antirheumatic drugs.
This website has been independently developed by Arthritis Australia for Australian users. We thank our sponsors for their support for an unrestricted, educational grant to fund its creation.
© Copyright Arthritis Australia 2020 | Website by Commune Digital